依达拉奉在急性脑梗死患者中的临床疗效观察

Study on the application of edaravone in acute cerebral infarction

目的:探讨依达拉奉治疗急性脑梗死患者的临床疗效,以及减轻脑水肿和降低血清超敏C-反应蛋白水平的价值。方法:选取符合标准的急性脑梗死患者100例,随机分为观察组和对照组各50例,2组患者均给予常规治疗,同时,观察组加用依达拉奉注射液30 mg,静脉滴注,bid;对照组给予吡拉西坦注射液8.0g,静脉滴注,qd;2组患者疗程均为14 d。分别于治疗前和治疗后7,14 d评价患者的脑水肿体积和血清超敏C-反应蛋白水平;疗程结束后,评价临床治疗效果。结果:观察组总有效率为86.00%,明显高于对照组的70.00%,二者差异有显著性(P<0.05);血清超敏C-反应蛋白水平及脑水肿体积较治疗前均下降(P<0.05),但观察组下降更明显(P<0.01)。结论:依达拉奉可以显著减轻急性脑梗死患者的脑水肿程度,改善神经缺损症状,提高临床疗效,值得临床推广应用。

OBJECTIVE To investigate the efficacy of edaravone treatment in patients with acute cerebral infarction,and ex- plore its clinical value for reducing cerebral edema and serum high-sensitivity C-reactive protein levels. METHODS A standard- selected 100 patients with acute cerebral infarction were randomly divided into two groups：the treatment group and the control group （50 patients in each group） ;both groups of patients were given conventional treatment, while the patients of treatment group were treated with edaravone injection 30 rag, intravenous infusion 2 times a day; the control group was given piracetam in-jection 8. 0 g,intravenous infusion, q. d; the therapeutic courses of the two groups were 14 days. The cerebral edema volumes and serum high-sensitivity C-reactive protein levels were assessed before and 7,14 days after treatment respectively; at the end of the treatment the clinical therapeutic effects were evaluated. RESULTS The total effective rate of the treatment group was 86. 00M,significantly higher than that of 70. 00% in the treatment group, the difference was statistically significant （P〈0. 05） ; after treatment, the high-sensitivity C-reactive protein levels and brain edema cell volumes in patients of both groups de- creased significantly than before treatment （P〈0. 05）, but in the patients of the treatment group were decreased more signifi- cantly （P〈0. 01）. CONCLUSION Edaravone can significantly reduce acute cerebral edema and improve neurological deficit symptoms, improve clinical efficacy, it is worthy of clinical application.